Discussion

MaxSimil® Patented Lipid Absorption Enhancement Technology (PLATform)
The MaxSimil PLATform is a novel monoglyceride delivery system that enhances absorption of lipid-based
and lipid-soluble nutraceutical and food ingredients. This technology has been applied to Cell Fx Omega |
650’s Product Name formulas in order to create a unique vehicle by which to deliver EPA and DHA. Due to
the fact that monoglyceride oils are intrinsically emulsifiers and are, by nature, in a readily absorbable form,
they can bypass the body’s normal fat digestion process. These qualities make Product Name an excellent
method for delivering omega-3 fatty acids, especially to individuals with digestive, pancreatic, or gall bladder
challenges. Studies show that MaxSimil fish oils (FO) have three times (300%) greater absorption of EPA and
DHA compared to other leading fish oils.*[1-3]

Quality

Product Name formulas are made using proprietary MaxSimil compositions containing monoglyceride FO with
no additional ingredients, carriers, or excipients. Each fish-gelatin softgel is enteric-coated, and every batch
of fish oil ensure the world’s highest standards for purity, potency, and freshness. The fish oil is non-GMO,
certified sustainable from Scandinavia, and antibiotic-free. Additionally, it is eco-friendly because the greater
absorption of EPA and DHA ultimately means that fewer grams of fish oil need to be harvested for the same
benefit.*

In Vitro and In Vivo Animal Studies

The ability of MaxSimil-enhanced EPA and DHA to positively influence growth inhibition and apoptosis in
colorectal, breast, lung, and prostate diseased cell lines was first demonstrated in a series of in vitro studies.
[4-6] Researchers subsequently set out to demonstrate efficacy in animal models after oral administration. In
three separate animal models, MaxSimil EPA and DHA forms showed superior activity on diseased cell-line
growth inhibition and cytokine production when compared to control, corn oil, krill oil, or the parent forms ethyl
ester (EE) EPA and ethyl ester (EE) DHA.[4,7,8] These in vivo animal studies proved that orally supplemented
MaxSimil EPA and DHA were well-absorbed and bioactive. Researchers postulated that the observed superior
effects of MaxSimil EPA and DHA forms were the result of enhanced absorption, and they set out to prove this
hypothesis.*

Preclinical Bioavailability Studies

The in vivo pharmacokinetic studies in rodents involved a comparison between MaxSimil DHA FO and its
parent EE DHA FO and an analysis of blood concentrations of DHA over time. The doses used were equivalent
to human doses of 3 g/day and 30 g/day; the latter was included primarily to investigate toxicity at high doses.
Researchers found that MaxSimil DHA FO had a three times (3x) higher peak concentration, a 3x higher
saturation potential at the high dose, and a 3x higher absorption rate (at a 3 g/day equivalent human dose)
than its parent DHA FO. No toxicity was observed at either dose level.[1,2] This research demonstrated superior
bioavailability and presumably better exposure of cells to DHA.*

Clinical Bioavailability Study

A phase 1, double-blind, randomized, crossover, pharmacokinetic study was performed in 20 healthy adults
aged between 19 and 71 years who were administered 6 g (containing 1800 mg EPA and 1200 mg DHA) per
day of EE FO or MaxSimil FO.[3] Parameters studied were plasma EPA and DHA concentration (as percent of
total fatty acids), Cmax, and AUC. Compared to EE EPA+DHA, the results indicated that at peak concentration,
MaxSimil EPA and DHA forms were 3x higher, they reached maximum concentration faster, and maintained
their plasma levels longer. The finding in the animal study was validated: the MaxSimil FO instantaneous
absorption was 3x greater than the EE form. Likewise, the AUC over 24 hours was also more than 3x higher
(P<.0001) for MaxSimil EPA and DHA (MaxSimil FO).*
Not only did this study confirm the bioavailability findings in the animal study, but it also demonstrated that after
24 hours, the MaxSimil FO maintained 2-3x higher blood levels of EPA and DHA than the EE FO. This means
that, given a daily dose, circulating EPA and DHA levels can be expected to ramp up over time and remain
high with steadily increasing exposure of cells to EPA, DHA, and their metabolites. Based on the results of the
bioavailability studies, an individual would get more EPA and DHA from MaxSimil FO than from EE FO gram
for gram. Furthermore, as shown in the animal studies, one could anticipate enhanced effects. It is noteworthy
that all 20 adults who completed the study saw their omega-3 absorption enhanced when taking the MaxSimil
enhanced FO.*

Expanding Research

In vitro and animal studies have demonstrated the positive effects of MaxSimil FO on airway immune response
(e.g., IgE, leukocytes); the expression of COX-2, NF-kB, cytokines (e.g., IL-6, IL-8), MUC5AC, and mucin; and
Ca(2+) hypersensitivity in lung tissues.[8-11] In other research, rats subjected to eight weeks of a high-fat, highcarbohydrate
diet were either not supplemented or provided 3 g/day of MaxSimil DHA. Compared to the data
from the non-supplemented group, the data from the MaxSimil DHA supplemented group clearly showed a
positive impact on cardiovascular health parameters. Measures included blood pressure, heart rate, serum lipid
levels, cytokine production, aortic wall thickness, and a DHA:AA ratio in aortic tissue, which correlated with the
production of resolvin D2 and D3 metabolites.*[12]

A Note About Resolvins and Other EPA and DHA Metabolites

Specialized proresolving lipid mediators, such as resolvins, protectins, and maresins, are EPA and DHA
metabolites naturally produced in vivo through enzymatic conversion of EPA and DHA. These mediators aid
the body’s “clean-up” response to the arachidonic acid cascade.[13] Rather than supplying a single molecule or
metabolite, which would mirror the pharmaceutical model, Product Name fish oils provide all the benefits of EPA
and DHA as well as the expected and desirable benefits of their metabolites.*

Arthricor®: Product Name MD

Each softgel of Product Name MD provides 500 mg of MaxSimil FO combined with 50 mg of Arthricor olive
leaf extract. It is generally accepted that the Mediterranean diet is beneficial to cardiovascular health,[14-16] and
research suggests that olive oil and its phenolic constituents are primary contributors.[17-21] Taking Arthricor olive
leaf extract daily provides the polyphenolic benefits of eating five olives or 50 mL of olive oil each day. Phenolic
compounds, as found in Arthricor, have been shown to have a protective effect against LDL oxidation.[19,22,23]
Arthricor provides three polyphenols—hydroxytyrosol, oleuropein, and tyrosol—for maximum benefit.*